Core Points - The company announced a capital increase plan, distributing 0.3 shares for every share held, approved at the 2024 annual general meeting on May 21, 2025 [2][4] - The total number of shares before the increase is 78,738,639, with 932,283 shares in the repurchase account excluded, resulting in 77,806,356 shares eligible for the distribution [4][5] - After the capital increase, the total number of shares will rise to 102,080,546, with an estimated diluted earnings per share of 0.08 yuan for the 2024 fiscal year [8] Capital Increase Plan - The capital increase is based on the total shares eligible for distribution, calculated as 77,806,356 shares, with a distribution ratio of 0.3 [5] - The reference price for the ex-rights and ex-dividend will be calculated based on the previous closing price adjusted for the increase in shares [5] - The capital increase will not incur any tax as it is derived from the capital reserve formed by the premium from share issuance [7] Implementation Details - The capital increase will be executed by the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, directly credited to the shareholders' accounts based on their holdings as of the record date [6] - The company will not provide cash dividends or bonus shares in this distribution [5] - Shareholders in the repurchase account will not participate in this capital increase [3]

中泰证券股份有限公司 关于湖南麒麟信安科技股份有限公司 差异化权益分派的核查意见 中泰证券股份有限公司（以下简称"中泰证券"或"保荐机构"）作为湖南 麒麟信安科技股份有限公司（以下简称"麒麟信安"或"公司"）首次公开发行 股票并在科创板上市的持续督导机构，根据《中华人民共和国公司法》《中华人 民共和国证券法》《证券发行上市保荐业务管理办法》《上海证券交易所科创板 股票上市规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》 等有关规定，对麒麟信安 2024 年度利润分配及资本公积金转增股本实施涉及的 差异化权益分派事项进行了核查，核查情况如下： 一、本次差异化权益分派的原因 2024 年 1 月 24 日，公司召开第二届董事会第五次会议和第二届监事会第五 次会议，审议通过了《关于以集中竞价交易方式回购公司股份方案的议案》，同 意公司使用首次公开发行人民币普通股取得的部分超募资金以集中竞价交易方 式回购公司已发行的部分人民币普通股股份，回购股份用于维护公司价值及股东 权益。本次回购股份的资金总额不低于人民币 3,500.00 万元（含），不高于人民 币 6,000.00 万元（含），本次回购股份的 ...

证券代码：688152 证券简称：麒麟信安 公告编号：2025-052 湖南麒麟信安科技股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所 | | 股权登记日 | | 除权（息）日 | 新增无限售条件流通股份 | | --- | --- | --- | --- | --- | | | | | | 上市日 | | 2025/6/12 | | 2025/6/13 | | 2025/6/13 | 一、 通过转增股本方案的股东大会届次和日期 本次转增股本方案经公司2025 年 5 月 21 日的2024年年度股东大会审议通过。 二、 转增股本方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东（公 司回购专用证券账户中的股份不参与本次权益分派）。 公司存在首发战略配售股份，首发战略配售股份已全部上市流通 是否涉及差 ...

湖南麒麟信安科技股份有限公司（以下简称"公司"）于近日收到政府补助款 项合计 717.39 万元，属于与收益相关的政府补助款项。 二、补助的类型及其对公司的影响 根据《企业会计准则第 16 号-政府补助》的有关规定，公司获得的上述政府 补助属于与收益相关的政府补助。上述政府补助未经审计，具体的会计处理及对 公司 2025 年度损益的影响，最终以审计机构年度审计确认后的结果为准，敬请 投资者注意投资风险。 特此公告。 证券代码：688152 证券简称：麒麟信安 公告编号：2025-051 湖南麒麟信安科技股份有限公司 关于获得政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、获得补助的基本情况 湖南麒麟信安科技股份有限公司 董事会 2025 年 6 月 4 日 ...

Group 1 - The core viewpoint highlights the positive performance of the AI sector in China, particularly through the rise of the STAR Market AI ETF, which has seen a net inflow of nearly 25 million yuan over two days [1] - The STAR Market AI ETF closely tracks the Shanghai STAR Market AI Index, which consists of 30 large-cap companies providing foundational resources, technology, and application support for AI [1] - According to the "2025 China AI Computing Power Development Assessment Report," China's intelligent computing power is expected to grow significantly, with a projected increase of 43% by 2025 compared to 2024, and potentially doubling by 2026 [1] Group 2 - CITIC Securities notes that the AI industry in China has gained sustained attention from society, driven by the breakout effect of DeepSeek, with upcoming releases of DeepSeekR2 and GPT-5 expected to continue the revaluation of the tech sector [2] - UBS highlights that international market interest in Chinese assets is increasing, supported by improved market liquidity, which enhances investor confidence and attracts long-term overseas investors [2] - The appeal of new productive forces, particularly in AI and high-end manufacturing, is driving a shift in the narrative logic of the Chinese stock market [2]

证券代码：688152 证券简称：麒麟信安 公告编号：2025-049 湖南麒麟信安科技股份有限公司 关于注销部分募集资金专户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 截至本公告披露日，公司已将存放在湖南银行股份有限公司湘江新区分行（专户账号： 79010309000109954）的募集资金全部转至公司自有资金账户，用于永久补充流动资金，并办理完成该 募集资金专户的注销手续。上述募集资金专户注销后，公司与该募集资金专户开户银行、保荐机构签署 的《募集资金专户存储三方监管协议》相应终止。 特此公告。 一、募集资金基本情况 经中国证券监督管理委员会《关于同意湖南麒麟信安科技股份有限公司首次公开发行股票注册的批复》 （证监许可【2022】2092号）核准，湖南麒麟信安科技股份有限公司（以下简称"麒麟信安"或"公司"） 向社会公开发行人民币普通股（A股）1,321.1181万股，发行价格为68.89元/股，募集资金总额为人民币 910,118,259.09元，扣除本次发行费用人民币76,927,075.33元（不含税 ...

Group 1 - Guangdian Electric's wholly-owned subsidiary plans to sell 5.91% stake in Shanghai Winshun Electric Technology Co., Ltd. to Yapp Automotive Parts Co., Ltd. for 62.63 million yuan, aiming to optimize asset structure [1] - Anhui Natural Gas received approval for the registration of 500 million yuan short-term financing bonds and 600 million yuan medium-term notes, valid for two years [1] - Kirin Security received government subsidies totaling 6.48 million yuan, which are related to revenue [2] Group 2 - Junshi Biosciences received approval for two new indications for its self-developed drug, Oncorhynchus monoclonal antibody injection, targeting adult patients with heterozygous familial hypercholesterolemia and non-familial hypercholesterolemia [3] - China Resources Double Crane's subsidiary passed GMP compliance inspection for small and large volume injection production lines [4] - Nanjing Public Utilities' board approved the absorption and merger of its wholly-owned subsidiary, Nanjing Jinguang Industry Co., Ltd. [7] Group 3 - Boya Bio received drug registration certificate for human immunoglobulin (pH4) in the Dominican Republic, valid until August 12, 2029 [8] - Jizhi Co. announced that its controlling shareholder and actual controller committed not to reduce their shareholdings until December 31, 2025 [9] - Yuhua Tian won a bid for the integrated urban management project in Lanzhou City, with a total service subsidy of 353 million yuan [10] Group 4 - Anke Rui obtained five invention patent certificates related to various energy management and control technologies [11] - Kebo Da's wholly-owned subsidiary plans to acquire 100% of Czech IMI Company for approximately 9.43 million euros to enhance global production layout [13] - Yantian Port announced a cash dividend of 1.30 yuan per 10 shares, totaling 676 million yuan [14] Group 5 - Huawang Technology plans to distribute a cash dividend of 0.45 yuan per share and a capital reserve increase of 0.20 shares per share [15] - Kabe Yi established a wholly-owned subsidiary in Japan to enhance its business layout [16] - Dongcheng Pharmaceutical's subsidiary received approval for the marketing of sodium fluoride injection, a PET radiopharmaceutical [18] Group 6 - Huaxin New Materials' subsidiary received two utility model patent certificates for innovative devices [19] - Lingang Steel's new 2290 cubic meter blast furnace has been successfully put into operation [21] - Xinlitai received drug registration certificate for Sacubitril/Valsartan tablets, the first of its kind in China [23] Group 7 - Aike Co.'s subsidiary received project designation notices from multiple clients for electric drive platform components [25] - Tonghe Pharmaceutical received drug registration certificate for Apixaban in South Korea [26] - Junting Hotel signed a cooperation agreement with Choice Hotels for exclusive brand usage in mainland China [28] Group 8 - Guangdong Hongtu plans to establish a wholly-owned subsidiary in Zhengzhou to enhance market layout [30] - Yuheng Pharmaceutical signed a joint promotion agreement for Pemafibrate tablets with Xinghe Pharmaceutical [31] - Chongqing Steel terminated the absorption and merger of its wholly-owned subsidiary, citing strategic advantages of independent operation [33] Group 9 - Jihong Co. announced the listing of its H-shares on the Hong Kong Stock Exchange [34] - Deshi Co. announced plans for shareholders to reduce their holdings by up to 0.3% [36] - Xinhai Medical's subsidiary received medical device registration for a dialysis fluid filter [42]

证券代码：688152 证券简称：麒麟信安 公告编号：2025-050 一、获得补助的基本情况 湖南麒麟信安科技股份有限公司（以下简称"公司"）及控股子公司麒麟信安 （广东）科技有限公司于近日收到政府补助款项合计 647.99 万元，属于与收益 相关的政府补助款项。 湖南麒麟信安科技股份有限公司 关于公司及子公司获得政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 特此公告。 湖南麒麟信安科技股份有限公司 董事会 2025 年 5 月 28 日 二、补助的类型及其对公司的影响 根据《企业会计准则第 16 号-政府补助》的有关规定，公司获得的上述政府 补助属于与收益相关的政府补助。上述政府补助未经审计，具体的会计处理及对 公司 2025 年度损益的影响，最终以审计机构年度审计确认后的结果为准，敬请 投资者注意投资风险。 ...

证券代码：688152 证券简称：麒麟信安 公告编号：2025-049 湖南麒麟信安科技股份有限公司 关于注销部分募集资金专户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 经中国证券监督管理委员会《关于同意湖南麒麟信安科技股份有限公司首次 公开发行股票注册的批复》（证监许可【2022】2092 号）核准，湖南麒麟信安 科技股份有限公司（以下简称"麒麟信安"或"公司"）向社会公开发行人民币普通 股（A 股）1,321.1181 万股，发行价格为 68.89 元/股，募集资金总额为人民币 910,118,259.09 元，扣除本次发行费用人民币 76,927,075.33 元（不含税）后，实 际募集资金净额为人民币 833,191,183.76 元。上述募集资金已于 2022 年 10 月 20 日全部到位，天职国际会计师事务所（特殊普通合伙）对本次发行募集资金到账 情况进行了审验，并出具了天职业字[2022]41533 号《验资报告》。 二、募集资金管理情况 公司于 2025 年 2 月 14 ...

麒麟信安公告，公司及控股子公司麒麟信安(广东)科技有限公司近日收到政府补助款项合计647.99万 元，属于与收益相关的政府补助款项。上述政府补助未经审计，具体的会计处理及对公司2025年度损益 的影响，最终以审计机构年度审计确认后的结果为准。 ...